Preterm Birth Prevention and Management Market – By Therapy Type, By Route of Administration, By Distribution Channel, Global Forecast, 2025 to 2034

Preterm Birth Prevention and Management Market Size

The global preterm birth prevention and management market was valued at USD 1.8 billion in 2024 and is expected to exhibit growth at a CAGR of 7.7% from 2025 to 2034. The market growth is attributed to the increasing preterm birth rates, advancements in medical technology, rising prevalence of maternal risk factors, and growing focus on neonatal care, among other contributing factors.
 

The preterm birth remains a primary cause of neonatal morbidity and mortality worldwide. For instance, according to the World Health Organization (WHO), an estimated 15 million babies are born preterm each year, and this number is rising. Additionaly, in 2022, preterm birth complications were responsible for approximately 1 million deaths in children under five years. The increasing incidence of preterm births has created a higher demand for prevention and management solutions, driving market expansion.
 

Moreover, technological innovations in prenatal care, such as improved diagnostic tools, monitoring systems, and treatments, are enabling better management of high-risk pregnancies, leading to enhanced outcomes for preterm infants
 

Preterm birth prevention and management refers to the strategies and medical interventions aimed at preventing or managing premature births (before 37 weeks of gestation). This includes the use of therapies like progesterone, tocolytics, corticosteroids, and magnesium sulfate to delay labor, promote fetal lung maturity, and manage complications.
 

Preterm Birth Prevention and Management Market Trends

The market is experiencing several market trends that are shaping its growth and development. Factors such as increasing use of digital health solutions, growth in personalized medicine, and increased research and development in drug therapy, among other factors are boosting the industry growth.
 

• Further, there is a growing trend toward personalized approaches to preterm birth prevention. Healthcare providers are increasingly using genetic screening, biomarkers, and individual risk profiles to tailor treatment plans for pregnant women. This trend allows for more targeted and effective prevention and management strategies, driving demand for personalized care solutions.
   
• Moreover, the use of artificial intelligence in healthcare and machine learning in the prediction and management of preterm birth is on the rise. AI algorithms are being used to analyze patient data, such as medical history, lifestyle factors, and prenatal screenings, to predict the likelihood of preterm birth. These technologies are enhancing early risk detection and enabling healthcare providers to deliver more accurate, personalized care, thereby aforementioned factors are expected to drive the market.
   

Preterm Birth Prevention and Management Market Analysis 

Based on therapy type, the market is segmented as progesterone therapy, corticosteroid therapy, tocolytic therapy, antibiotics therapy, heparin prophylaxis therapy, and other therapy types. The progesterone therapy segment is expected to drive business growth and expand at a CAGR of 8%, reaching over USD 1.5 billion by 2034.
 

• Progesterone has been extensively studied and shown to significantly reduce the risk of preterm birth in women with a history of spontaneous preterm birth or those identified as being at high risk. Its proven efficacy in preventing early labor—particularly in women with a short cervix or multiple pregnancies—is a key driver of its widespread use in preterm birth prevention.
   
• Additionally, as the prevalence of high-risk pregnancies increases due to factors such as advanced maternal age, obesity, and multiple gestations, there is a growing need for effective interventions like progesterone therapy. This rise in at-risk pregnancies is fueling the demand for progesterone treatments, which remain one of the most reliable methods for preventing preterm labor, thereby contributing to the segment's growth.
   

Based on route of administration, the market is segmented into parenteral, oral, and topical. The parenteral segment is expected to drive business growth and expand at a CAGR of 7.6%, reaching over USD 2.7 billion by 2034.
 

• Parenteral administration, particularly through intravenous (IV) or intramuscular (IM) routes, ensures faster and more effective delivery of drugs like progesterone or tocolytics. These treatments are critical in preventing preterm birth, especially in high-risk pregnancies, as they bypass the digestive system and provide more reliable and controlled dosing, driving their adoption in clinical settings.
   
• Moreover, it allows for the rapid absorption of drugs into the bloodstream, resulting in a faster onset of action. This is crucial in the management of preterm labor, where prompt intervention is needed to prevent or delay early delivery. The ability to act quickly makes parenteral treatments a preferred option for healthcare providers managing preterm birth risks, which is expected to boost the growth of this segment in the market.
   

Based on distribution channel, the market is classified into brick and mortar and e-commerce. The brick and mortar segment dominated the market with a revenue share of 82.5% in 2024.
 

• Brick-and-mortar healthcare facilities are essential for providing a wide range of maternal and fetal care services, including prenatal screenings, progesterone therapy, and specialized preterm birth management. As healthcare infrastructure improves, more pregnant women, particularly those at high risk, are seeking care at these facilities, driving the demand for preterm birth prevention and management services.
   
• Furthermore, hospitals and clinics staffed by obstetricians, neonatologists, and maternal-fetal medicine specialists offer specialized care for high-risk pregnancies. These professionals are crucial in diagnosing and managing conditions that may lead to preterm birth, such as cervical insufficiency or preeclampsia. The presence of these experts in brick-and-mortar facilities supports the effective delivery of preterm birth prevention strategies, driving market demand for such institutions.
   

U.S. preterm birth prevention and management market accounted for USD 671.6 million in 2024 and is anticipated to grow at a CAGR of 7.2% between 2025 to 2034 period.
 

• The U.S. has a relatively high rate of preterm births compared to other developed countries, with around 10% of births occurring prematurely. This high prevalence creates a pressing need for effective preterm birth prevention and management strategies. The ongoing challenge of reducing preterm birth rates fuels the demand for advanced treatments, therapies, and diagnostic solutions in the U.S. healthcare system.
   
• In addition, the country is home to cutting-edge research and advancements in maternal-fetal medicine, including the development of new technologies, therapies, and medical practices for preventing and managing preterm births. Innovations in genetic screening, biomarkers, and medical devices used to monitor pregnancy risks contribute to the growing market for preterm birth prevention and management in the U.S.
   

Germany preterm birth prevention and management market is projected to grow remarkably in the coming years.
 

• Germany has a well-established healthcare system with high-quality maternal and neonatal care facilities. The availability of advanced hospitals, clinics, and specialized maternal-fetal medicine centers provides the infrastructure necessary for the effective prevention and management of preterm births. The country's healthcare system ensures that high-risk pregnancies are closely monitored and managed, driving demand for preterm birth prevention solutions.
   
• Furthermore, the country is at the forefront of medical technology and innovation, particularly in the field of obstetrics. The availability of advanced diagnostic tools, such as ultrasounds, fetal monitoring systems, and genetic screening, enables healthcare providers to detect preterm birth risks early and manage pregnancies more effectively. These technologies are critical in preventing and managing preterm births, driving the demand for related services and products in the country.
   

China holds a dominant position in the Asia Pacific preterm birth prevention and management market.
 

• The growing use of ART, such as in vitro fertilization (IVF), is contributing to a higher incidence of high-risk pregnancies and preterm births in China. Women who undergo fertility treatments are more likely to experience preterm labor, which drives the need for preterm birth prevention and management interventions, including progesterone therapy and other medical interventions.
   
• Further, the development of maternal-fetal medicine in China has led to better recognition and treatment of preterm birth risks. The use of advanced diagnostic tools, such as ultrasound and genetic screening, allows for early identification of women at risk of preterm labor, facilitating timely interventions and the adoption of preterm birth prevention measures, which is driving market growth.
   

Preterm Birth Prevention and Management Market Share

The market is characterized by a mix of pharmaceutical companies, medical device manufacturers, and healthcare providers offering a range of products and services. Key players focus on developing advanced treatments, such as progesterone therapies, tocolytics, and diagnostic tools for early detection. Additionally, hospitals and specialized maternal care centers play a crucial role in providing management solutions. The market is highly competitive, with companies investing in R&D and strategic partnerships to improve preterm birth prevention strategies and enhance maternal and neonatal health outcomes.
 

Preterm Birth Prevention and Management Market Companies

Prominent players operating in the preterm birth prevention and management industry include:

• AbbVie
• AMAG Pharmaceuticals
• Ferring Pharmaceutical
• Merck
• Obseva
• Pfizer
• Takeda Pharmaceutical
   

Preterm Birth Prevention and Management Industry News:

• In March, 2021, Covis Group has announced that updated results from the EPPPIC study showed 17-OHPC and vaginal progesterone effectively reduce the risk of early preterm birth in high-risk singleton pregnancies before 34 weeks. This strengthens company's market position, particularly for 17-OHPC, by confirming its efficacy and reinforcing its role in preterm birth prevention.
   

The preterm birth prevention and management market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Therapy Type

• Progesterone therapy
• Corticosteroid therapy
• Tocolytic therapy
• Antibiotics therapy
• Heparin prophylaxis therapy
• Other therapy types

Market, By Route of Administration

• Parenteral
• Oral
• Topical

Market, By Distribution Channel

• Brick and mortar
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE